Search research articles
Contact Us
Filters
Showing results (301-310 of 314) with videos related to
Page
of 32
Sort By:
JAMA Oncology
|
May 26, 2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
Jeremy M O'Connor, Kristen L Fessele, Jean Steiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2012
American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care
Thomas J Smith, Sarah Temin, Erin R Alesi, et al.
Journal of the American Medical Informatics Association : JAMIA
|
March 7, 2019
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Arlene E Chung, Kimberly Shoenbill, Sandra A Mitchell, et al.
Journal of Translational Medicine
|
November 23, 2012
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
Antoni Ribas, Jason A Chesney, Michael S Gordon, et al.
The Oncologist
|
December 29, 2018
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
Sean Khozin, Kenneth R Carson, Jizu Zhi, et al.
JCO Clinical Cancer Informatics
|
July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer
Mark Stewart, Andrew D Norden, Nancy Dreyer, et al.
Contemporary Clinical Trials
|
April 15, 2017
Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART
Sarah A Kelleher, Caroline S Dorfman, Jen C Plumb Vilardaga, et al.
JMIR Human Factors
|
July 18, 2018
Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study
Martin W Schoen, Ethan Basch, Lori L Hudson, et al.
Journal of Palliative Medicine
|
November 26, 2010
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group
Amy P Abernethy, Noreen M Aziz, Ethan Basch, et al.
Translational Behavioral Medicine
|
September 28, 2013
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Deborah Watkins Bruner, Laura J Hanisch, Bryce B Reeve, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 314) with videos related to
Sort By:
Page
of 32
JAMA Oncology
|
May 26, 2018
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
Jeremy M O'Connor, Kristen L Fessele, Jean Steiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2012
American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care
Thomas J Smith, Sarah Temin, Erin R Alesi, et al.
Journal of the American Medical Informatics Association : JAMIA
|
March 7, 2019
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Arlene E Chung, Kimberly Shoenbill, Sandra A Mitchell, et al.
Journal of Translational Medicine
|
November 23, 2012
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
Antoni Ribas, Jason A Chesney, Michael S Gordon, et al.
The Oncologist
|
December 29, 2018
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
Sean Khozin, Kenneth R Carson, Jizu Zhi, et al.
JCO Clinical Cancer Informatics
|
July 24, 2019
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer
Mark Stewart, Andrew D Norden, Nancy Dreyer, et al.
Contemporary Clinical Trials
|
April 15, 2017
Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART
Sarah A Kelleher, Caroline S Dorfman, Jen C Plumb Vilardaga, et al.
JMIR Human Factors
|
July 18, 2018
Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study
Martin W Schoen, Ethan Basch, Lori L Hudson, et al.
Journal of Palliative Medicine
|
November 26, 2010
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group
Amy P Abernethy, Noreen M Aziz, Ethan Basch, et al.
Translational Behavioral Medicine
|
September 28, 2013
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Deborah Watkins Bruner, Laura J Hanisch, Bryce B Reeve, et al.
Page
of 32